Innovating Works
HORIZON-CL4-2024-RESILIENCE-01-36
HORIZON-CL4-2024-RESILIENCE-01-36: Advanced biomaterials for the Health Care (IA)
Expected Outcome:This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.
Sólo fondo perdido 0 €
European
This call is closed This line is already closed so you can't apply. It closed last day 07-02-2024.
An upcoming call for this aid is expected, the exact start date of call is not yet clear.
Hace más de 16 mes(es) del cierre y aún no tenemos información sobre los proyectos financiados, no parece que se vaya a publicar esta información.
Presentation: Consortium Consortium: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Minimum number of participants.
This aid finances Proyectos:

Expected Outcome:This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.

Projects are expected to contribute to the following outcomes:

Develop the swiftly growing innovation market of medical applications, which is dependent on advanced biocompatible materials that can be printed or injected, including 4D materials that change their 3D structures following external impact (e.g. thermic, electric, mechanical or radiation treatment).Medical and/or surgical procedures will benefit from injectable materials for non-invasive surgical procedures.Some of their advantages include easy deliverability into the body, increased implantation precision, controllable release of therapeutic agents, antimicrobial properties and the possibility of monitoring or stimulating biologi... see more

Expected Outcome:This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.

Projects are expected to contribute to the following outcomes:

Develop the swiftly growing innovation market of medical applications, which is dependent on advanced biocompatible materials that can be printed or injected, including 4D materials that change their 3D structures following external impact (e.g. thermic, electric, mechanical or radiation treatment).Medical and/or surgical procedures will benefit from injectable materials for non-invasive surgical procedures.Some of their advantages include easy deliverability into the body, increased implantation precision, controllable release of therapeutic agents, antimicrobial properties and the possibility of monitoring or stimulating biological events. Medical suppliers can commercialise injectable hydrogels, including those made of nanocomposite, natural and synthetic polymer-based biomaterials, bone cements, bio-ceramics and electronics.

Scope:Proposals should address at least four of the following activities:

To enable a fast development of new advanced novel injectable biomaterials, digital tools such as modelling, simulation and characterisation techniques (including those provided by analytical infrastructures) assisted by advanced methods e.g. physics-based methods, machine learning or artificial intelligence.The innovation market of medical applications is fast growing and dependent on advanced biocompatible materials that can be printed or injected. The 4D materials will change their 3D structures after external impact such as thermic, electric, mechanical or radiation treatment.Proposals shall demonstrate new engineering strategies that present functional characteristics beyond bio-compatibility, and express properties that can be used to control the physiological environment (shape-memory, self-healing properties) and induce a response.Proposals shall address biomaterials with antibacterial properties contributing to the widespread bottleneck of antimicrobial resistance often encountered in clinical careDemonstrate the scaling of injectable hydrogels, including those made of nanocomposite, natural and synthetic polymer-based biomaterials, bone cements, bio-ceramics and electronics.The design for circularity has to develop, when relevant, bio-degradable or bio-absorbable biomaterials that are gradually eliminated by the body after fulfilling a purpose. The biomaterials used should be safe and sustainable by design (SSbD), taking also into account any specific medical requirements.

Proposals submitted under this topic should include a business case and exploitation strategy, as outlined in the introduction to this Destination.

This topic requires the effective contribution of SSH disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities. An early involvement of end users could be essential.

Projects should build on or seek collaboration with existing projects and develop synergies with other relevant European, national or regional initiatives, funding programmes and platforms.#

Where relevant, proposals should seek links with and capitalise on the results of past and ongoing EU funded research projects, including the ones under Cluster 1 “Health” and Cluster 6 'Food, Bioeconomy, Natural Resources, Agriculture and Environment.

see less

Temáticas Obligatorias del proyecto: Temática principal: Chemical engineering Materials engineering Medical biotechnology Medical engineering Nano-technology

Consortium characteristics

Scope European : The aid is European, you can apply to this line any company that is part of the European Community.
Tipo y tamaño de organizaciones: The necessary consortium design for the processing of this aid needs:

characteristics of the Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Expected Outcome:This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy. Expected Outcome:This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Several materials specifications and related innovations needs will support this topic such as renewable and recyclable materials, alternative active ingredients, design for circularity, lightweight materials. The topic should address several key policies of the European Union such as Circular Economy Action Plan, EU Chemicals strategy.
Financial Chapters: The chapters of financing expenses for this line are:
Personnel costs.
Expenses related to personnel working directly on the project are based on actual hours spent, based on company costs, and fixed ratios for certain employees, such as the company's owners.
Subcontracting costs.
Payments to external third parties to perform specific tasks that cannot be performed by the project beneficiaries.
Purchase costs.
They include the acquisition of equipment, amortization, material, licenses or other goods and services necessary for the execution of the project
Other cost categories.
Miscellaneous expenses such as financial costs, audit certificates or participation in events not covered by other categories
Indirect costs.
Overhead costs not directly assignable to the project (such as electricity, rent, or office space), calculated as a fixed 25% of eligible direct costs (excluding subcontracting).
Madurez tecnológica: The processing of this aid requires a minimum technological level in the project of TRL 6:. Se cuenta con prototipos piloto capaces de desarrollar todas las funciones necesarias dentro de un sistema determinado, habiendo superado pruebas de factibilidad en condiciones de operación o funcionamiento real. + info.
TRL esperado:

Characteristics of financing

Intensidad de la ayuda: Sólo fondo perdido + info
Lost Fund:
0% 25% 50% 75% 100%
For the eligible budget, the intensity of the aid in the form of a lost fund may reach From a 70% up to a 100%.
The funding rate for IA projects is 70 % for profit-making legal entities and 100 % for non-profit legal entities. The funding rate for IA projects is 70 % for profit-making legal entities and 100 % for non-profit legal entities.
Guarantees:
does not require guarantees
No existen condiciones financieras para el beneficiario.

Additional information about the call

incentive effect: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
non -competitive competitive Very competitive
We do not know the total budget of the line pero en los últimos 6 meses la línea ha concecido
total granted en los últimos 6 meses.
minimis: Esta línea de financiación NO considera una “ayuda de minimis”. You can consult the regulations here.

other advantages

SME seal: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-CL4-2024-RESILIENCE-01-TWO-STAGE Advanced biomaterials for the Health Care (IA) Expected Outcome:This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Severa...
Sin info.
HORIZON-CL4-2024-RESILIENCE-01-36 Advanced biomaterials for the Health Care (IA)
en consorcio: Expected Outcome:This topic refers to the innovation market for Healthcare and Medicine, which affects many citizens and their needs. Severa...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-CL4-2024-RESILIENCE-01-35 Biodegradable polymers for sustainable packaging materials (IA)
en consorcio: Expected Outcome:Projects are expected to contribute to the following outcomes: The packaging industry will have access to the next generat...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-CL4-2024-RESILIENCE-01-04 Technologies for processing and refining of critical raw materials (IA)
en consorcio: ExpectedOutcome:Projects outcomes will enable achieving the expected impacts of the destination by increasing access to primary raw material...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-CL4-2024-RESILIENCE-01-01 Exploration of critical raw materials in deep land deposits (RIA)
en consorcio: ExpectedOutcome:Projects outcomes will enable achieving the expected impacts of the destination by increasing access to primary raw material...
Cerrada does 1 year | next call scheduled for the month of
HORIZON-CL4-2024-RESILIENCE-01-10 Addressing due diligence requirements in raw materials supply chains. (CSA)
en consorcio: ExpectedOutcome:Projects outcomes will enable achieving the expected impacts of the destination by increasing access to primary raw material...
Cerrada does 1 year | next call scheduled for the month of